2016 wasn't especially kind to Juno Therapeutics Inc JUNO stock. Shares of the small cap biopharmaceutical have lost more than 25 percent of their value year-to-date.
Nonetheless, over the past month, the stock staged a rebound, recuperating more than 12.6 percent. The Vetr crowd seems to believe the rally will continue, as evidenced by its average price target of $38.02, which implies a potential return of roughly 16 percent from current valuations.
Related Link: Here's How Crowdsourced Ratings Can Beat The Market
Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Juno on Monday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.
It should be noted that, in accordance with the new rating, 84 percent of the crowd’s ratings are bullish.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.